Coronavirus Disease Mortality and Outcome in Macedonian Patients With Chronic Lymphocytic Leukemia: Single-Center Experience
Clinical Lymphoma Myeloma and Leukemia
; 22:S274, 2022.
Article
in English
| ScienceDirect | ID: covidwho-2042264
ABSTRACT
Context Patients with chronic lymphocytic leukemia (CLL) may be more predisposed to coronavirus disease 2019 (COVID-19) due to age, the nature of the disease, and treatment-related immunosuppression. Objective:
The aim of the study was to assess risk factors of the outcome and course of COVID-19 for CLL patients in Macedonia.Design:
Retrospective study of patients with CLL and COVID-19 infection in the period of time from the beginning of the pandemic to March 2022.Setting:
Individual patient data from 55 CLL patients with COVID-19 infection were analyzed. The risk factors of COVID-19 disease severity and outcomes were investigated.Interventions:
The outcome was the analysis of patients with COVID-19 infection in line with host risk factors and biological heterogeneity of the disease with previous therapy for CLL.Results:
Our evaluation has shown that 80% of patients were male and 20% were female. The average age was 65 years. The average CIRS score was 2 and BMI was 23.6. Most of the patients (67.2%) have unmutated Ig genes. Ninety-one percent (91%) from that subgroup of patients have a severe form of COVID-19, 82% of patients were treated with chemotherapy, and 48% had a fatal outcome.Conclusions:
CLL-directed treatment and unmutated Ig genes were significant risk factors for survival. Untreated patients and patients with mutated IGHV had a better chance of survival than those on treatment or who were recently treated.
Full text:
Available
Collection:
Databases of international organizations
Database:
ScienceDirect
Type of study:
Prognostic study
Language:
English
Journal:
Clinical Lymphoma Myeloma and Leukemia
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS